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biological and cellular aging and has been asso‑
ciated with the development of HF.7 The severity 
of myocardial fibrosis is another abnormality ob‑
served in elderly patients, and is associated with 
increased susceptibility to HF.8
In the study by Ozieranski et al,1 most of the pa‑
tients with HF under the age of 75 years were 
male, but over the age of 75 years, the sex dis‑
tribution was almost equal because of the in‑
crease in the number of women with HF. In the 
Polish ESC‑HF Long‑Term Registry, the risk of 
death or rehospitalization was shown to increase 
with age over 75 years old, which is consistent 
with the findings of other studies.2,4,9 Howev‑
er, the study lacks data on the sex distribution 
of patients with HF‑PEF and the number of pa‑
tients with acute HF. This information would veri‑
fy the results of some studies which revealed that 
elderly patients hospitalized for acute HF are more 
likely to be female and to have higher ejection frac‑
tion and a higher prevalence of HF‑PEF compared 
with younger patients.2,10,11 These patients also 
have an increased prevalence of comorbidities in‑
cluding AF, hypertension, cerebrovascular disease, 
anemia, and renal failure.10‑12 On the other hand, 
CAD and diabetes are less common in very elder‑
ly patients (>75 years old).2,9‑12 This may be ex‑
plained by the longer survival of patients without 
these diseases, which, on the other hand, causes 
systolic dysfunction and HF at a younger age.13
In contrast to younger patients with HF, el‑
derly patients with acute decompensation of HF 
more often present with acute pulmonary ede‑
ma and hypertension, which is consistent with 
a significant vascular contribution to the under‑
lying pathophysiology.2 Conversely, elderly per‑
sons with chronic HF may present with a gradual 
onset of symptoms and atypical findings, includ‑
ing loss of appetite, tiredness, and global weak‑
ness, whereas traditional HF symptoms may be 
absent or difficult to interpret due to the lack of 
specificity.
Despite contemporary therapeutic options, heart 
failure (HF) is a growing public health problem, 
especially in elderly population.
In an article by Ozieranski et al,1 the authors 
made an attempt at assessing the clinical pro‑
file and 1‑year outcomes of 765 elderly patients 
hospitalized for HF decompensation and partic‑
ipating in the Polish ESC‑HF Long‑Term Regis‑
try. Patients aged 65 years or older were com‑
pared with those younger than 65 years of age. 
An additional subanalysis sought to determine 
the clinical differences among elderly patients 
aged from 65 to 74 years and the very elderly, 
aged 75 years or older.1
Nowadays, it is particularly important to in‑
vestigate the clinical characteristics of elderly pa‑
tients as well as the effects of contemporary thera‑
pies on the outcomes of these patients. This is be‑
cause most clinical trials on HF excluded this pop‑
ulation, especially persons over 75 years of age.2,3
Except more frequent comorbidities such as 
hypertension, coronary artery disease [CAD], or 
atrial fibrillation[AF], aging is associated with 
specific changes to cardiac structure and func‑
tion, which may explain a number of pathophysi‑
ological and phenotypic features typical for the el‑
derly.2 Among these, particularly important is 
the greater predisposition of these patients to de‑
velop HF, especially HF with preserved ejection 
fraction (HF‑PEF).4,5 These changes involve the re‑
duction in the number of myocytes and regener‑
ative capacity of cardiac progenitor cells, which 
occurs even in individuals without evidence of 
cardiovascular disease.5 The loss of functioning 
cardiomyocytes is compensated by hypertrophy 
of the remaining cells.5,6 Alterations in the func‑
tion of myocytes associated with older age also 
include impaired calcium metabolism and reg‑
ulation, as well as secondary less efficient ade‑
nosine triphosphate ATP utilization, which re‑
flects changes in the processes of contraction and 
relaxation of the heart muscle.1 The shortening 
of telomeres has been suggested as a marker of 
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There is also little known on the response to 
pharmacological treatment in elderly patients. 
Ozierański et al,1 in their analysis of the Polish 
ESC‑HF Long‑Term Registry, demonstrated that 
treatment with β‑blockers results in a 50% re‑
duction of the risk of death at 1 year, but only in 
patients younger than 75 years old.1 This find‑
ing has not been unequivocally confirmed in 
the study, but the authors provided a possible 
explanation: it might be due to a decreasing use 
of appropriate doses of β‑blockers and a worse 
response to β‑adrenergic blockade in the elderly 
population. In addition, possible cognitive im‑
pairment and financial problems may affect treat‑
ment adherence.2
Data from recent trials investigating the ef‑
fects of β‑blockers in elderly patients are still in‑
sufficient. Admittedly, in the SENIORS study with 
nebivolol and the CIBIS‑ELD study with biso‑
prolol, which were cited by Ozieranski et al1 in 
their research, the mean age of patients was over 
73 years, but in other studies with β‑blockers, 
like COPERNICUS or BEST, the participants were 
much younger (mean age, about 60 years).2
The lack of evidence‑based therapies in the el‑
derly represents a  major challenge because 
the management of a medical therapy is a com‑
plex process for several reasons. First of all, drug 
pharmacokinetics changes during the aging pro‑
cess because of a reduction in lean body mass and 
total body water, reduction in the metabolic ca‑
pacity of the liver, and a decrease in renal func‑
tion.14 Furthermore, treatment comorbidities of‑
ten accompanying old age require polypharma‑
cy, which results in a higher risk of drug interac‑
tions and side effects.2,14 Some comorbidities and 
their treatments may by themselves contribute 
to the worsening of HF.15 By contrast, invasive 
strategies of HF treatment, such as cardioverter‑ 
‑defibrillator implantation or cardiac resynchro‑
nization therapy, are performed less frequently 
in patients over 75 years of age because of short‑
er life expectancy, so our knowledge on this sub‑
ject is still insufficient.2
In conclusion, although the definition of old 
age is 65 years or older, the elderly population is 
extremely diverse in terms of health condition 
and prognosis. In addition, increased life expec‑
tancy may make this age cut‑off too low. Elderly 
patients represent the majority of the population 
with HF and have worse prognosis compared with 
the younger HF cohort. Target treatment strate‑
gies have been insufficiently developed for elder‑
ly patients, and a multidisciplinary approach and 
further research on this population (especially 
individuals over 75 years of age) are necessary.
